Tidal Investments LLC lifted its holdings in shares of Grifols, S.A. (NASDAQ:GRFS – Free Report) by 9.8% during the 2nd quarter, Holdings Channel reports. The firm owned 1,233,082 shares of the biotechnology company’s stock after buying an additional 109,612 shares during the period. Tidal Investments LLC’s holdings in Grifols were worth $8,730,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Allworth Financial LP grew its stake in shares of Grifols by 15.7% in the fourth quarter. Allworth Financial LP now owns 8,073 shares of the biotechnology company’s stock worth $75,000 after acquiring an additional 1,096 shares in the last quarter. Cerity Partners LLC raised its stake in shares of Grifols by 6.3% in the fourth quarter. Cerity Partners LLC now owns 19,121 shares of the biotechnology company’s stock valued at $179,000 after acquiring an additional 1,131 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in Grifols by 10.1% in the first quarter. Bank of New York Mellon Corp now owns 16,419 shares of the biotechnology company’s stock valued at $132,000 after purchasing an additional 1,511 shares during the period. Versant Capital Management Inc boosted its holdings in Grifols by 36.0% in the second quarter. Versant Capital Management Inc now owns 6,958 shares of the biotechnology company’s stock valued at $49,000 after purchasing an additional 1,842 shares during the period. Finally, Franklin Resources Inc. grew its stake in Grifols by 10.9% during the 4th quarter. Franklin Resources Inc. now owns 21,343 shares of the biotechnology company’s stock worth $200,000 after purchasing an additional 2,104 shares in the last quarter.
Wall Street Analysts Forecast Growth
Several equities research analysts have weighed in on GRFS shares. Wall Street Zen downgraded Grifols from a “buy” rating to a “hold” rating in a report on Monday, May 18th. Weiss Ratings upgraded Grifols from a “sell (d)” rating to a “sell (d+)” rating in a research note on Monday, August 17th. Finally, Zacks Research raised Grifols from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 7th. Two analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Grifols has a consensus rating of “Reduce” and a consensus price target of $10.00.
Grifols Price Performance
Shares of GRFS opened at $7.55 on Friday. The firm has a market capitalization of $5.14 billion, a price-to-earnings ratio of 39.74, a PEG ratio of 0.28 and a beta of 0.67. The firm’s fifty day simple moving average is $7.73 and its 200-day simple moving average is $7.89. Grifols, S.A. has a twelve month low of $6.96 and a twelve month high of $10.23. The company has a current ratio of 2.37, a quick ratio of 0.81 and a debt-to-equity ratio of 1.10.
Grifols Announces Dividend
The firm also recently declared a special dividend, which was paid on Thursday, July 9th. Shareholders of record on Thursday, July 2nd were paid a $0.0945 dividend. The ex-dividend date was Thursday, July 2nd. Grifols’s dividend payout ratio (DPR) is currently 42.11%.
Grifols Profile
Grifols SA is a global healthcare company headquartered in Barcelona, Spain, and listed on Nasdaq under the symbol GRFS. Founded in 1909, the company specializes in plasma-derived medicines and other products used to treat chronic and rare diseases.
Its biopharma business develops and manufactures therapies derived from human plasma, including immunoglobulins, albumin, coagulation factors and alpha-1 antitrypsin. These products support patients with immune deficiencies, bleeding disorders, liver conditions and certain respiratory diseases.
See Also
- Five stocks we like better than Grifols
- Rocket Lab Tackles a Supply Chain Bottleneck as the Stock Hunts for a Bottom. Time to Buy?
- Optical Cable Corporation Is Starting to Get the Market’s Attention
- Oil Above $100 Is Creating a New Opportunity Beyond the Major Producers
- Is Nike’s Index Demotion a Warning or a Buying Opportunity?
Want to see what other hedge funds are holding GRFS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Grifols, S.A. (NASDAQ:GRFS – Free Report).
Receive News & Ratings for Grifols Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols and related companies with MarketBeat.com's FREE daily email newsletter.
